In the two studies on [18F]FMM the tracer dose and the group composition of the disease of interest differs (CA vs. ATTR), but TBRmean values were comparable between early and late acquisition for the amyloidosis and non-amyloidosis groups. This evidence concerns the gene TTR and amyloidosis.